Understanding Multiple Primary Cancers
Determining How Estrogen Alterations and Cancer Treatment Impact 2nd Cancer Risk for Individuals with the KRAS-variant
Individuals who carry the KRAS-variant are at greater risk of developing breast, ovarian, and lung cancers. Recent studies also show women with this marker are up to eleven times as likely to develop a second, independent breast cancer. The overall goal of this study is to determine how to prevent multiple primary cancers in patients with the KRAS-variant.
We believe that management strategies applied during a first breast cancer diagnosis may change the risk of a second breast cancer for women with the KRAS–variant. Management strategies may include hormone therapies (e.g., tamoxifen, arimidex, etc.), surgery (e.g., preventive mastectomy), and chemotherapy.
In this study we will investigate two things, first, how common a family history of multiple primary cancers is for people with the KRAS-variant, and second, for women with breast cancer, which strategy for breast cancer management is safest for women with the KRAS-variant. (Note: a second, independent breast cancer is not the same as a recurrence of the first breast cancer.)
If you are interested in participating in this research study, please complete our eligibility survey:
Apply to Participate!
Once you submit your survey, here is what you can expect:
- A MiraKind researcher will review your survey information, and you will then be sent the protocol and a consent to review.
- You will be given the contact information for a MiraKind researcher to ask any questions you may have about the study, before you consent.
- Once your questions have been answered you will be able to electronically sign the consent, and you will be enrolled in the study and sent your DNA collection kit.
- You will receive a follow up study specific questionnaire, as well as information on how to obtain individual results through a physician of your choice if you are interested in doing so.
- If you are not eligible for any MiraKind studies that are currently open but would like to stay updated on forthcoming studies, please join our e-newsletter.
- Here are some additional resources about MiraKind and this study: